Immunovant (NASDAQ:IMVT) vs. Genfit (NASDAQ:GNFT) Head to Head Analysis

Genfit (NASDAQ:GNFT) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Profitability

This table compares Genfit and Immunovant’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genfit	N/A	N/A	N/A
Immunovant	N/A	-56.40%	-52.03%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Genfit and Immunovant, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genfit	0	0	1	0	3.00
Immunovant	0	1	10	0	2.91

Genfit presently has a consensus target price of $13.00, indicating a potential upside of 265.68%. Immunovant has a consensus target price of $47.00, indicating a potential upside of 103.90%. Given Genfit’s stronger consensus rating and higher possible upside, equities analysts plainly believe Genfit is more favorable than Immunovant.

Risk and Volatility

Genfit has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500.

Institutional and Insider Ownership

2.2% of Genfit shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 4.2% of Genfit shares are owned by company insiders. Comparatively, 5.9% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Genfit and Immunovant”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genfit	$76.06 million	2.34	-$31.27 million	N/A	N/A
Immunovant	N/A	N/A	-$259.34 million	($2.22)	-10.38

Genfit has higher revenue and earnings than Immunovant.

Summary

Genfit beats Immunovant on 7 of the 10 factors compared between the two stocks.

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

About Immunovant

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.